These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: [Results of radiotherapy of bronchial carcinoma (author's transl)].
    Author: Heilmann HP, Doppelfeld E, Fernholz HJ, Birkner R, Schlicker H, Becker G, Gordon-Harris L, Hackl A, Sager WD, Jentsch F, Kraft W, Bünemann H, Horstmann W, Hassenstein E, Kuttig H, Wieland C, Schmidt N, Müller A, Quäck J, Buchelt L, Hess F, Koop EA, von Lieven H, Heinze HG, Castrup W, Wannenmacher M, Rey G, Voss AC, Nüse A, Eibach E, Grund W, Bohndorf W, Schindler G.
    Journal: Dtsch Med Wochenschr; 1976 Oct 22; 101(43):1557-62. PubMed ID: 62648.
    Abstract:
    In a joint retrospective study by 17 radiotherapy clinics in German-speaking countries the results of treatment of bronchial carcinoma after radiotherapy were analysed in 7503 cases. The age peak was between the 60th and 70th year. Squamous-cell carcinoma was the most frequent histological type, followed by anaplastic carcinoma, with adenocarcinoma being rare. There was a high proportion of histologically not clearly identified cases (27% in central and 35% in peripheral carcinomas). Survival rate at one year was 31% for central (3662 patients) and peripheral (961 patients) tumours, but only 2% at five years. Prognostically there was no difference between histological types and kind of radiotherapy or technique, but total dose affected survival rate. At a total dose of less than 5000 rd the survival rate at five years was minimal. The prognosis of combined surgical and radiotherapeutic measures was slightly better than with a radiotherapy alone, but results were unpredictable for the individual case. It is concluded that radiotherapy aiming at cure should be used in imoperable bronchial carcinoma if the tumour state and general condition of the patient appear to make a cure possible. But if this is not the case, radiotherapy should be used only palliatively, i.e. only to ameliorate symptoms.
    [Abstract] [Full Text] [Related] [New Search]